Sophiris Bio (Sophiris Bio) Institutional Ownership : 3.89% (As of May. 06, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sophiris Bio's institutional ownership is 3.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sophiris Bio's Insider Ownership is 0.11%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sophiris Bio's Float Percentage Of Total Shares Outstanding is 87.50%.

Sophiris Bio Institutional Ownership Historical Data

The historical data trend for Sophiris Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Institutional Ownership Chart

Sophiris Bio Historical Data

The historical data trend for Sophiris Bio can be seen below:

	2020-06-30	2020-07-31	2020-08-31	2020-09-30	2020-10-31	2020-11-30	2020-12-31	2021-01-31	2021-02-28	2021-03-31
Institutional Ownership	3.89	3.89	3.89	3.89	3.89	3.89	3.89	3.89	3.89	3.89

Sophiris Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Sophiris Bio (Sophiris Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

1258 Prospect Street, La Jolla, CA, USA, 92037

Website

http://www.sophirisbio.com

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

Executives

Randall E Woods	director, officer: President & Chief Exec Officer	C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell	director
Gerald T Proehl	director
John Geltosky	director	685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn	director	PO BOX 676367, RANCHO SANTA FE CA 92067